Practical Neurology Podcast

Rituximab in neuroinflammatory conditions: the evidence available and prescribing advice

The basic principles of B-cell depletion with therapeutic monoclonal antibodies, the available evidence for using rituximab in neurological diseases as well as prescribing advice are discussed in this podcast.
Practical Neurology Associate Editor Dr Tom Hughes is joined by Dr Daniel Whittam and Dr Anu Jacob, the authors of the review paper: “Rituximab in neurological disease: principles, evidence and practice”, which is part of the Practical Neurology February issue (https://pn.bmj.com/content/19/1/5).

Cannabis licensing and epilepsy: addressing the challenges for doctors and patients

What do adult neurologists need to know ahead of the likely licensing of Epidiolex for epilepsy in the UK in 2019? It is quite possible that cannabidiol, currently licensed in the USA for treating rare genetic epilepsies, may open the door for the widespread legalisation of recreational cannabis.
Dr Rhys Thomas (Neurologist at the Institute of Neuroscience, Newcastle University, UK) tells fellow Practical Neurology Associate Editor Dr Tom Hughes why the arguments about who may benefit from cannabis-derived medicines have to be separate from the discussion about the legalisation of recreational cannabis. They also discuss the distinction between cannabidiol oils and the cannabidiol rigorously tested in clinical trials.
Read the review on the Practical Neurology website - https://pn.bmj.com/content/early/2018/10/18/practneurol-2018-002058 - and on the journal's December 2018 issue.

Valproate contraindicated in pregnancy: new regulations and advice for neurologists

Valproate is now contraindicated in pregnancy and women of child-bearing potential. The new stipulations from the Coordination Group for Mutual Recognition and Decentralised Procedures-Human (CMDh), a regulatory body representing European Union member states, about the use of valproate in women of child-bearing potential states that “Valproate should never be started unless alternative treatments are not suitable”. However, people taking this drug used to treat epilepsy should not stop valproate use abruptly, without consulting their doctor.
The new regulations are discussed in this podcast by Professor Sanjay Sisodiya (UCL Institute of Neurology, London), who’s the author of a Practical Neurology editorial on this subject (http://pn.bmj.com/content/early/2018/04/19/practneurol-2018-001955).
Other related articles in the Practical Neurology website:
►http://pn.bmj.com/content/early/2018/04/19/practneurol-2018-001932
► http://pn.bmj.com/content/early/2018/04/19/practneurol-2018-001931

Duchenne’s muscular dystrophy - from gene discovery to treatment

Professor Michael Hanna, Senior Consultant Neurologist at Queen Square, UCL, London, discusses the developments in genetics in neuromuscular diseases with Eric Hoffman, Gordon Holmes lecturer at the ABN meeting 2017, in Liverpool.
Professor Eric Hoffman (Binghampton University, USA) describes in this conversation his extensive work on the rare condition of Duchenne’s muscular dystrophy.
This is the last of a series of podcasts recorded at the 2017 ABN meeting, held in May, in Liverpool, UK.
More on this subject on the Practical Neurology website: http://pn.bmj.com/, where you can find these particular articles as well:
"Muscle disease" - http://pn.bmj.com/content/9/1/54;
"Muscle diseases: mimics and chameleons" - http://pn.bmj.com/content/14/5/288.

Nodding syndrome: a public health issue in children of South Sudan, Uganda and Tanzania

Nodding syndrome affects children from 5 to 15 years old in some parts of the African continent. In this podcast, David Nicholl, Department of Neurology, City Hospital, Birmingham, UK, is joined by Mark Ellul, ABN fellow, University of Liverpool, UK, to discuss the latest research in this epileptic disorder.
They talked at the Association of British Neurologists annual meeting, Liverpool, May 2017.
http://pn.bmj.com/

ABN Annual Meeting: Professor Andrew Schwartz and the high-performance neural prosthetics

Professor Andrew Schwartz (University of Pittsburgh, USA) discusses the latest progress toward high-performance neural prosthetics with Practical Neurology's editor Geraint Fuller. The subject was highlighted at the ABN annual meeting 2017, held in May, in Liverpool, UK.
For more content on this topic please visit http://pn.bmj.com/.

ABN Annual Meeting 2017: Interview with Kevin Talbot

At the ABN annual meeting 2017, David Burn interviews Kevin Talbot on the his talk on Antisense treatments in spinal muscular atrophy.
The ABN Autumn Meeting took place on Wednesday 3rd May in Liverpool.
For more content on this topic please visit: pn.bmj.com/

ABN Autumn Lecture: Antisense treatments in neurological disease

Based on the ABN's Autumn Meeting, Martin Turner interviews Matthew Wood on the his lecture Antisense treatments in neurological disease.
The ABN Autumn Meeting took place on 20th October 2016 in London.
For more content on this topic please visit: pn.bmj.com/

ABN Autumn Lecture: Treatable hereditary neuropathies

Based on the ABN's Autumn Meeting, David Nicholl interviews Mary Reilly on the her lecture Treatable Hereditary Neuropathies.
The ABN Autumn Meeting took place on 20th October 2016 in London.
For more content on this topic please visit: pn.bmj.com/

ABN Autumn Lecture: Functional movement disorders - phenomenology and management

Based on the ABN's Autumn Meeting, David Nicholl interviews Mark Edwards on his lecture Functional Movement Disorders - Phenomenology and Management.
The ABN Autumn Meeting took place on 20th October 2016 in London.
Recommended articles on this topic include:
Explaining functional disorders in the neurology clinic: a photo story
Alan Carson, Alexander Lehn, Lea Ludwig, Jon Stone
pn.bmj.com/content/16/1/56
Functional neurological symptoms: welcome to the new normal
Mark J Edwards
pn.bmj.com/content/16/1/2
Functional neurological disorders: the neurological assessment as treatment
Jon Stone
http://pn.bmj.com/content/16/1/7